OPTI Medical Systems, Inc. products

Our next generation of blood gas analyzers. The OPTI CCA-TS2 Blood Gas and Electrolyte Analyzer: Provides fast accurate results for blood gases, acid-base balance, electrolytes, ionized calcium, glucose, BUN and lactate. Runs samples of whole blood, plasma and serum on single-use disposable cassettes. Uses innovative optical technology. Requires minimal maintenance.

The OPTI CCA and OPTI CCA-TS Blood Gas and Electrolyte Analyzers: Provides fast accurate results for blood gases, acid-base balance, electrolytes, ionized calcium, glucose, BUN and lactate. Runs samples of whole blood, plasma and serum on single-use disposable cassettes. Uses innovative optical technology. Requires minimal maintenance.

OPTI Medical Systems has obtained CE marking for its OPTI SARS-CoV-2/Influenza A/B RT-PCR Test for identification and differentiation of SARS-CoV-2, influenza A, and influenza B RNA. The test is available in countries accepting the CE mark. This respiratory panel distinguishes between SARS-CoV-2 and influenza A and B extracted from nasopharyngeal swabs. Use of this test is ideal for identifying the cause of symptoms during influenza season.

OPTI Medical Systems has obtained CE marking for its OPTI SARS-CoV-2 Total Antibody Test for detection of total antibodies against SARS-CoV-2. The OPTI SARS-CoV-2 Total Antibody Test is an enzyme-linked immunosorbent assay (ELISA) that detects total antibodies (IgG, IgM, and IgA) against the receptor binding domain (RBD) of the spike (S) protein of SARS-CoV-2 in samples from human serum and plasma. Given that current vaccines have been developed to elicit antibodies against the receptor binding domain of the spike protein, this test is an excellent tool for assessing vaccine-elicited antibody uptake.

OPTI Medical Systems has received US FDA Emergency Use Authorization and CE mark for its OPTI SARS-CoV-2 RT-PCR Test for detection of the virus causing COVID-19. The OPTI SARS-CoV-2 RT-PCR Test is based on real-time reverse transcription polymerase chain reaction (RT-PCR), which provides detection of the viral RNA in the sample. The test can be used on both individual samples as well as in pools of 5 samples for screening purposes. It is designed for the detection of SARS-CoV-2 RNA extracted from nasopharyngeal swabs, oropharyngeal swabs and other upper respiratory sample types, collected from any individual, including from individuals without symptoms or other reasons to suspect COVID-19 infection.